Day, Bryan W. http://orcid.org/0000-0002-8948-9089
Lathia, Justin D.
Bruce, Zara C.
D’Souza, Rochelle C. J.
Baumgartner, Ulrich
Ensbey, Kathleen S.
Lim, Yi Chieh
Stringer, Brett W.
Akgül, Seçkin
Offenhäuser, Carolin
Li, Yuchen
Jamieson, Paul R.
Smith, Fiona M.
Jurd, Courtney L. R.
Robertson, Thomas
Inglis, Po-Ling
Lwin, Zarnie
Jeffree, Rosalind L.
Johns, Terrance G.
Bhat, Krishna P. L.
Rich, Jeremy N.
Campbell, Kevin P.
Boyd, Andrew W.
Funding for this research was provided by:
National Health and Medical Research Council (NHMRC) - Australia (I.D.1078893)
Sid Faithfull Group
Cure Brain Cancer Foundation
Paul D. Wellstone Muscular Dystrophy Cooperative Research Center (1U54NS053672)
Article History
Received: 9 May 2019
Revised: 21 August 2019
Accepted: 22 August 2019
First Online: 28 August 2019
Compliance with ethical standards
:
: The authors declare no competing interests.
: Consent to utilise de-identified information from human brain cancer specimens were obtained through a Patient Information Consent Form (PICF) detailed in the Project Outline 29,917 for HREC/17/QRBW/577: Novel Therapies for Brain Cancer.
: Human brain cancer specimens were collected from the Royal Brisbane and Women’s Hospital (RBWH) under Human Ethics approved project HREC/17/QRBW/577: Novel Therapies for Brain Cancer. All mice experiments were performed according to the National Health and Medical Research Council (2013) Australian code for the care and use of animals for scientific purposes, under experimental protocols approved by the QIMR Berghofer Animal Ethics Committee.